iBio (IBIO) 10-Q 18 Nov 16 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2016	Nov. 18, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	iBio, Inc.
Entity Central Index Key	1,420,720
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	IBIO
Entity Common Stock, Shares Outstanding		89,109,410

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Current assets:
Cash	$ 20,098	$ 23,014
Accounts receivable - trade	170	484
Accounts receivable - unbilled	62	122
Work in process	0	22
Prepaid expenses and other current assets	132	264
Total Current Assets	20,462	23,906
Fixed assets, net of accumulated depreciation	25,580	25,574
Intangible assets, net of accumulated amortization	2,023	2,092
Security deposit	26	28
Total Assets	48,091	51,600
Current liabilities:
Accounts payable (related party of $239 and $200 as of September 30, 2016 and June 30, 2016, respectively)	979	1,177
Accrued expenses (related party of $772 and $623 as of September 30, 2016 and June 30, 2016 respectively)	1,022	920
Capital lease obligation - current portion	173	170
Deferred revenue	0	24
Total Current Liabilities	2,174	2,291
Capital lease obligation - net of current portion	25,220	25,265
Total Liabilities	27,394	27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,109,410 shares issued and outstanding as of September 30, 2016 and June 30, 2016	89	89
Additional paid-in capital	67,733	67,468
Accumulated other comprehensive loss	(29)	(29)
Accumulated deficit	(60,652)	(57,591)
Total iBio, Inc. Stockholders’ Equity	7,141	9,937
Noncontrolling interest	13,556	14,107
Total Equity	20,697	24,044
Total Liabilities and Equity	$ 48,091	$ 51,600

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Accounts payable, related parties	$ 239	$ 200
Accrued expenses, related parties	$ 772	$ 623
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares issued (in shares)	89,109,410	89,109,410
Common stock, shares outstanding (in shares)	89,109,410	89,109,410

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenues	$ 135	$ 160
Operating expenses:
Research and development (related parties of $239 and $227), net of $36 and $0 in grant income	820	551
General and administrative (related parties of $175 and $0)	2,469	1,422
Total operating expenses	3,289	1,973
Operating loss	(3,154)	(1,813)
Other income (expense):
Interest expense (related party of $483 and $0)	(483)	0
Interest income	13	2
Royalty income	12	6
Total other income	(458)	8
Consolidated net loss	(3,612)	(1,805)
Net loss attributable to noncontrolling interest	551	0
Net loss attributable to iBio, Inc.	(3,061)	(1,805)
Comprehensive loss:
Net loss	(3,612)	(1,805)
Other comprehensive loss - foreign currency translation adjustments	0	(9)
Comprehensive loss	$ (3,612)	$ (1,814)
Loss per common share - basic and diluted	$ (0.03)	$ (0.02)
Weighted-average common shares outstanding - basic and diluted	89,109	77,307

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating expenses research and development, related party	$ 239	$ 227
Operating expenses general and administrative, related party	175	0
Interest Expense, Related Party	483	0
Revenue from Grants	$ 36	$ 0

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Equity - 3 months ended Sep. 30, 2016 - USD ($) shares in Thousands, $ in Thousands	Total	Other Comprehensive Income (Loss) [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Balance at Jun. 30, 2016	$ 24,044	$ (29)	$ 0	$ 89	$ 67,468	$ (57,591)	$ 14,107
Balance (in shares) at Jun. 30, 2016			0	89,110
Share-based compensation	265	0	$ 0	$ 0	265	0	0
Foreign currency translation adjustment	0	0	0	0	0	0	0
Net loss	(3,612)	0	0	0	0	(3,061)	(551)
Balance at Sep. 30, 2016	$ 20,697	$ (29)	$ 0	$ 89	$ 67,733	$ (60,652)	$ 13,556
Balance (in shares) at Sep. 30, 2016			0	89,110

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (3,612)	$ (1,805)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	265	329
Amortization of intangible assets	88	91
Depreciation	324	1
Changes in operating assets and liabilities:
Accounts receivable - trade	315	(34)
Accounts receivable - unbilled	61	(126)
Work in process	22	0
Prepaid expenses and other current assets	131	90
Security deposit	2	0
Accounts payable	53	171
Accrued expenses	102	136
Deferred revenue	(24)	0
Net cash used in operating activities	(2,273)	(1,147)
Cash flows from investing activities:
Additions to intangible assets	(202)	(18)
Purchases of fixed assets	(400)	0
Net cash used in investing activities	(602)	(18)
Cash flows from financing activities:
Payment of capital lease obligation	(41)	0
Proceeds from exercise of warrants	0	63
Net cash (used in) provided by financing activities	(41)	63
Effect of exchange rate changes	0	(8)
Net decrease in cash	(2,916)	(1,110)
Cash - beginning of period	23,014	9,494
Cash - end of period	20,098	8,384
Schedule of non-cash activities:
Unpaid intangible assets included in accounts payable	184	0
Unpaid fixed assets included in accounts payable	71	0
Unpaid intangible assets included in accrued expenses	0	(3)
Supplemental cash flow information:
Cash paid during the period for interest	$ 484	$ 0

Nature of Business

Nature of Business	3 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Nature of Business iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows: iBioDefense Biologics LLC (“iBioDefense”) – iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016. iBio Peptide Therapeutics LLC (“iBio Peptide”) – iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016. iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99 iBio Manufacturing LLC (“iBio Manufacturing”) – iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date. iBio CMO LLC (“iBio CMO”) – iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned 100 15 30 70 iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000 34

Basis of Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. Basis of Presentation Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2016, from which the accompanying condensed balance sheet dated June 30, 2016 was derived. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Liquidity The Company’s primary sources of liquidity are cash on hand and cash available from the sale of common stock of the Company. At this time, cash flows from operating activities represent net outflows for operating expenses and expenses for technology and product development. As of September 30, 2016, the Company had $ 20.1 Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of September 30, 2016, the Company’s accumulated deficit was $ 60.7 2.3 . On May 15, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) pursuant to which the Company has the option to require Aspire Capital, upon and subject to the terms of the agreement, to purchase up to $ 15 No shares have been sold under the 2015 Facility as of the date of the filing of this report. See Note 9 for a further description of the agreement. Coincident with the entry into the iBio CMO joint venture, Eastern agreed to acquire 10 0.622 3,500,000 6,500,000 1,784,000 0.53 15 7.2 10 The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Aspire Capital pursuant to the common stock purchase agreement entered into on May 15, 2015, and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. The Company's financial statements were prepared under the assumption that the Company will continue as a going concern. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 3 of the Notes to Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2016. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $ 36,000 Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016. Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years. Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5). The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23 In May 2014, ASU No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In June 2014, ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Effective January 1, 2016, the Company adopted ASU 2015-01, “ Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” Effective July 1, 2016, the Company adopted ASU 2015-02, “ Consolidation (Topic 810): Amendments to the Consolidation Analysis In November 2015, the FASB issued ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers In May 2016, the FASB issued ASU 2016-12, “ Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurement	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Financial Instruments and Fair Value Measurement The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company’s condensed consolidated balance sheets approximated their fair values as of September 30, 2016 and June 30, 2016 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value as of September 30, 2016 and June 30, 2016 as the interest rate used to discount the lease payments approximated market.

Fixed Assets

Fixed Assets	3 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Fixed Assets iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34 The economic substance of the sublease is that the Company is financing the acquisition of the facility and equipment and, accordingly, the facility and equipment are recorded as assets and the lease is recorded as a liability. As the sublease involves real estate and equipment, the Company separated the equipment component and accounted for the facility and equipment as if each was leased separately. September 30, June 30, 2016 2016 Facility under capital lease $ 20,000 $ 20,000 Equipment under capital lease 6,000 6,000 Facility improvements 57 42 Medical equipment 305 - Office equipment and software 146 137 26,508 26,179 Accumulated depreciation – assets under capital lease (882) (571) Accumulated depreciation – other (46) (34) (928) (605) Net fixed assets $ 25,580 $ 25,574 Depreciation expense was approximately $ 324,000 1,300 311,000 0

Intangible Assets

Intangible Assets	3 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). The Company designates such technology acquired from Fraunhofer as iBioLaunch technology or as iBioModulator technology. The value attributed to Patents owned or controlled by the Company is based on payments for services and fees related to the further development and protection of the Company’s patent portfolio. In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the “Licensed Technology”). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (“IND”) – became due on December 1, 2015. A six-month extension was automatically granted until June 1, 2016 under the license agreement. On August 11, 2016, the agreement was amended and replaced the original milestone schedule to provide that the IND filing be accomplished by June 30, 2017. The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges during Fiscal 2017 and Fiscal 2016. The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): September 30, June 30, 2016 2016 Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,284 2,265 5,384 5,365 Intellectual property – accumulated amortization (1,971) (1,932) Patents – accumulated amortization (1,390) (1,341) (3,361) (3,273) Net intangible assets $ 2,023 $ 2,092 Amortization expense was approximately $ 88,000 91,000

Significant Vendors

Significant Vendors	3 Months Ended
	Sep. 30, 2016
Significant Vendor [Abstract]
Significant Vendor Disclosures [Text Block]	7. Significant Vendors Fraunhofer Fraunhofer was the Company’s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below). The accounts payable balance under this three-party agreement includes amounts due Fraunhofer of approximately $ 122,000 341,000 $ 62,000 122,000 On January 4, 2011, the Company entered into the Collaboration and License Agreement (the “CLA”) which is a three-party agreement involving the Company, Fraunhofer and Fiocruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provides for the development of a Yellow Fever vaccine to be manufactured and distributed within Latin America and Africa by Fiocruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the “Agreement”). The services are billed to Fiocruz at Fraunhofer’s cost, so the Company’s revenue is equivalent to expense and there is no profit. On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. In Fiscal 2017 and Fiscal 2016, under the Amended Agreement, the Company recognized revenue of $ 62,000 160,000 In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. See Note 14 - Commitments and Contingencies for significant modifications. On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer's Executive Director. See Note 14 - Lawsuits for additional information. Novici Biotech, LLC In January 2012, the Company entered into an agreement with Novici Biotech, LLC (“Novici”) in which iBio’s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $ 239,000 200,000 239,000 227,000

Capital Lease Obligation

Capital Lease Obligation	3 Months Ended
	Sep. 30, 2016
Leases, Capital [Abstract]
Leases of Lessee Disclosure [Text Block]	8. Capital Lease Obligation As discussed above, iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34 2,100,000 In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. Interest expense incurred under the capital lease obligation amounted to approximately $ 484,000 0 Fiscal period ending on September 30,: Principal Interest Total 2017 $ 173,048 $ 1,926,952 $ 2,100,000 2018 186,593 1,913,407 2,100,000 2019 201,198 1,898,802 2,100,000 2020 216,947 1,883,053 2,100,000 2021 233,928 1,866,072 2,100,000 Thereafter 24,381,531 35,468,469 59,850,000 Total minimum lease payments 25,393,245 $ 44,956,755 $ 70,350,000 Less: current portion (173,048) Long-term portion of minimum lease obligations $ 25,220,197

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	9. Stockholders’ Equity Preferred Stock The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 Common Stock As of September 30, 2016 and 2015, the Company was authorized to issue up to 175 15 million shares No shares of common stock were issued for the period July 1, 2016 through the date of the filing of this report. Recent issuances of common stock include the following: Aspire Capital – 2015 Facility On May 15, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital, pursuant to which the Company has the option to require Aspire Capital to purchase up to an aggregate of $ 15.0 In consideration for entering into the purchase agreement, Aspire Capital received a commitment fee of 450,000 (the “Commitment Shares”) On any business day after the Commencement Date (as defined below) and over the 36-month term of the 2015 Aspire Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 200,000 500,000 2,000,000 In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital for at least 150,000 0.40 35 97 80 . The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice are determined at the Company’s discretion. The aggregate number of shares that the Company can sell to Aspire Capital under the 2015 Aspire Purchase Agreement may in no case exceed 15,343,406 19.99 450,000 The 2015 Aspire Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the 2015 Aspire Purchase Agreement could commence only after certain conditions were satisfied (the date on which all requisite conditions have been satisfied being referred to as the “Commencement Date”), which conditions included the delivery to Aspire Capital of a prospectus supplement covering the Commitment Shares and the Purchase Shares, approval for listing on NYSE MKT of the Purchase Shares and the Commitment Shares, the issuance of the Commitment Shares to Aspire Capital, and the receipt by Aspire Capital of a customary opinion of counsel and other certificates and closing documents. Either party had the option to terminate the 2015 Aspire Purchase Agreement in the event the Commencement Date had not occurred by July 1, 2015. The 2015 Aspire Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost or penalty. The Company’s net proceeds will depend on the Purchase Price, the VWAP Purchase Price and the frequency of the Company’s sales of Purchase Shares to Aspire Capital; subject to the maximum $ 15.0 In connection with the 2015 Aspire Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated May 15, 2015. The Registration Rights Agreement provides, among other things, a requirement to register the sale of the Commitment Shares and the Purchase Shares to Aspire Capital pursuant to the Company’s existing shelf registration statement (the “Registration Statement”). The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement. On May 29, 2015, the Company filed a prospectus supplement to the Company’s existing Registration Statement on Form S-3, registering $ 15.0 No shares have been sold under the 2015 Facility as of the date of the filing of this report. Eastern – Share Purchase Agreements On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 3,500,000 0.622 2,177,000 1,784,000 0.53 945,000 On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 6,500,000 0.622 6,500,000 6,500,000 4,043,000 38 Warrants The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. No warrants were outstanding as of September 30, 2016 and June 30, 2016.

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	10. Earnings (Loss) Per Common Share Three Months ended September 30, 2016 2015 Basic and diluted numerator: Net loss available to iBio, Inc. stockholders $ (3,061) $ (1,805) Basic and diluted denominator: Weighted-average common shares outstanding 89,109 77,307 Per Share Amount $ (0.03) $ (0.02) In Fiscal 2017 and Fiscal 2016, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2016, shares issuable which could potentially dilute future earnings included approximately 12.3 12.1 6.0

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. Share-Based Compensation Three Months Ended September 30, 2016 2015 Research and development $ 6 $ 5 General and administrative 259 324 Total $ 265 $ 329 Stock Options On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. The Plan, as amended on December 18, 2013, provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 15 2.7 No stock options were issued during Fiscal 2017. Weighted- Weighted- average average Remaining Aggregate Stock Exercise Contractual Intrinsic Value Options Price Term (in years) (in thousands) Outstanding as of July 1, 2016 12,273,334 $ 1.31 6.4 $ 993 Granted - Outstanding as of September 30, 2016 12,273,334 $ 1.31 6.1 $ 433 Vested and, as of September 30, 2016, expected to vest 12,233,897 $ 1.31 6.1 $ 433 Exercisable as of September 30, 2016 9,361,697 $ 1.31 5.5 $ 405 As of September 30, 2016, there was approximately $ 1.4 1.68

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions Novici Biotech, LLC In January 2012, the Company entered into an agreement with Novici in which iBio’s President is a minority stockholder. See Note 7. Agreements with Eastern Capital Limited and its Affiliates. As more fully discussed in Note 9, the Company entered into two share purchase agreements with Eastern and sold 10 0.622 6,220,000 1,784,000 0.53 945,000 Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio’s recently formed subsidiary, iBio CMO. The Eastern Affiliate contributed $ 15.0 30 70 In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CMO a 34 772,000 623,000 167,000 0 483,000 0 A three-year standstill agreement (the “Standstill Agreement”) that took effect upon the issuance of the Eastern Shares pursuant to the 6,500,000 38 Operating Lease with Minority Stockholder Effective January 1, 2015, the Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company. Rent was $ 2,200 2,500 7,500 6,600

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. Income Taxes The Company recorded no income tax expense for the three months ended September 30, 2016 and 2015 because the estimated annual effective tax rate was zero. As of September 30, 2016, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies Agreements In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. The significant modifications post June 30, 2013 are of follows: The Company’s obligation under the TTA, prior to the Settlement Agreement, to make three $ 1 3 2.7 3.0 The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $ 200,000 under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties. 4 On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) to create a new research and development plan for the development of a recombinant Yellow Fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. Under the CLA and bilateral agreement between iBio and Fraunhofer dated December 27, 2010, Fraunhofer, which has been engaged to act as the Company’s subcontractor for performance of research and development services for the new research and development plan, will bill Fiocruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement, and the proceeds of such billings and only the proceeds will be paid to Fraunhofer for its services so the Company’s expense is equal to its revenue and no profit is recognized for these activities under the Amended Agreement. For the year ended June 30, 2015, $ 2.1 3.0 On January 14, 2014 (the “Effective Date”), the Company entered into an exclusive worldwide License Agreement (“LA”) with the University of Pittsburgh (“UP”) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by UP pertinent to the use of endostatin peptides for the treatment of fibrosis. The Company paid an initial license fee of $ 20,000 30,627 25,000 150,000 On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (“MUSC”) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $ 78,000 December 31, 2015 161,754 Lawsuits On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. Briefing was completed on a motion to dismiss filed by Fraunhofer in lieu of filing an answer to the complaint. Fraunhofer also moved for a protective order in connection with certain discovery served by iBio. The Court bifurcated the action to first resolve the threshold question in the case – the scope of iBio’s ownership of the technology developed or held by Fraunhofer — before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties’ written submissions and oral argument on this threshold issue on April 29, 2016, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and is entitled to receive a transfer of the technology from Fraunhofer. On September 19, 2016, Fraunhofer informed the Court that it does not intend to pursue its motion for protective order at this time. iBio has sought leave of Court to supplement and amend its current complaint to add additional state law claims against Fraunhofer. Fraunhofer opposes this motion. The Company is unable to predict the further outcome of this action at this time. On December 4, 2015, a putative derivative action captioned Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant

Segment Reporting

Segment Reporting	3 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	15. Segment Reporting In accordance with FASB ASC 280, “ Segment Reporting Three Months Ended September 30, 2016 (in thousands) iBio, Inc. iBio CMO Eliminations Total Revenues - external customers $ 86 $ 49 $ - $ 135 Revenues – intersegment 152 182 (334) - Research and development 684 321 (185) 820 General and administrative 1,347 1,271 (149) 2,469 Operating loss (1,793) (1,361) - (3,154) Interest expense - (483) - (483) Interest and other income 18 7 - 25 Consolidated net loss (1,775) (1,837) - (3,612) Total assets 11,810 36,330 (49) 48,091 Fixed assets, net 8 25,572 - 25,580 Intangible assets, net 2,023 - - 2,023 Depreciation expense 1 323 - 324 Amortization of intangible assets 88 - - 88 Three Months Ended September 30, 2015 (in thousands) iBio, Inc. iBio CMO * Eliminations Total Revenues - external customers $ 160 $ - $ - $ 160 Revenues – intersegment - - - - Research and development 551 - - 551 General and administrative 1,422 - - 1,422 Operating loss (1,813) - - (1,813) Interest expense - - - - Interest and other income 8 - - 8 Consolidated net loss (1,805) - - (1,805) Total assets 11,374 - - 11,374 Fixed assets, net 10 - - 10 Intangible assets, net 2,284 - - 2,284 Depreciation expense 1 - - 1 Amortization of intangible assets 91 - - 91 * iBio CMO commenced operations in December 2015

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $ 36,000
Inventory Work in Process, Policy [Policy Text Block]	Work in Process Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016.
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years. Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In May 2014, ASU No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In June 2014, ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Effective January 1, 2016, the Company adopted ASU 2015-01, “ Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” Effective July 1, 2016, the Company adopted ASU 2015-02, “ Consolidation (Topic 810): Amendments to the Consolidation Analysis In November 2015, the FASB issued ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers In May 2016, the FASB issued ASU 2016-12, “ Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands): September 30, June 30, 2016 2016 Facility under capital lease $ 20,000 $ 20,000 Equipment under capital lease 6,000 6,000 Facility improvements 57 42 Medical equipment 305 - Office equipment and software 146 137 26,508 26,179 Accumulated depreciation – assets under capital lease (882) (571) Accumulated depreciation – other (46) (34) (928) (605) Net fixed assets $ 25,580 $ 25,574

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): September 30, June 30, 2016 2016 Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,284 2,265 5,384 5,365 Intellectual property – accumulated amortization (1,971) (1,932) Patents – accumulated amortization (1,390) (1,341) (3,361) (3,273) Net intangible assets $ 2,023 $ 2,092

Capital Lease Obligation (Table

Capital Lease Obligation (Tables)	3 Months Ended
	Sep. 30, 2016
Table Text Block Supplement [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Future minimum payments under the capitalized lease obligations are due as follows: Fiscal period ending on September 30,: Principal Interest Total 2017 $ 173,048 $ 1,926,952 $ 2,100,000 2018 186,593 1,913,407 2,100,000 2019 201,198 1,898,802 2,100,000 2020 216,947 1,883,053 2,100,000 2021 233,928 1,866,072 2,100,000 Thereafter 24,381,531 35,468,469 59,850,000 Total minimum lease payments 25,393,245 $ 44,956,755 $ 70,350,000 Less: current portion (173,048) Long-term portion of minimum lease obligations $ 25,220,197

Earnings (Loss) Per Common Sh27

Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts): Three Months ended September 30, 2016 2015 Basic and diluted numerator: Net loss available to iBio, Inc. stockholders $ (3,061) $ (1,805) Basic and diluted denominator: Weighted-average common shares outstanding 89,109 77,307 Per Share Amount $ (0.03) $ (0.02)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands): Three Months Ended September 30, 2016 2015 Research and development $ 6 $ 5 General and administrative 259 324 Total $ 265 $ 329
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes all stock option activity during Fiscal 2017: Weighted- Weighted- average average Remaining Aggregate Stock Exercise Contractual Intrinsic Value Options Price Term (in years) (in thousands) Outstanding as of July 1, 2016 12,273,334 $ 1.31 6.4 $ 993 Granted - Outstanding as of September 30, 2016 12,273,334 $ 1.31 6.1 $ 433 Vested and, as of September 30, 2016, expected to vest 12,233,897 $ 1.31 6.1 $ 433 Exercisable as of September 30, 2016 9,361,697 $ 1.31 5.5 $ 405

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, 2016 (in thousands) iBio, Inc. iBio CMO Eliminations Total Revenues - external customers $ 86 $ 49 $ - $ 135 Revenues – intersegment 152 182 (334) - Research and development 684 321 (185) 820 General and administrative 1,347 1,271 (149) 2,469 Operating loss (1,793) (1,361) - (3,154) Interest expense - (483) - (483) Interest and other income 18 7 - 25 Consolidated net loss (1,775) (1,837) - (3,612) Total assets 11,810 36,330 (49) 48,091 Fixed assets, net 8 25,572 - 25,580 Intangible assets, net 2,023 - - 2,023 Depreciation expense 1 323 - 324 Amortization of intangible assets 88 - - 88 Three Months Ended September 30, 2015 (in thousands) iBio, Inc. iBio CMO * Eliminations Total Revenues - external customers $ 160 $ - $ - $ 160 Revenues – intersegment - - - - Research and development 551 - - 551 General and administrative 1,422 - - 1,422 Operating loss (1,813) - - (1,813) Interest expense - - - - Interest and other income 8 - - 8 Consolidated net loss (1,805) - - (1,805) Total assets 11,374 - - 11,374 Fixed assets, net 10 - - 10 Intangible assets, net 2,284 - - 2,284 Depreciation expense 1 - - 1 Amortization of intangible assets 91 - - 91 * iBio CMO commenced operations in December 2015

Nature of Business (Details Tex

Nature of Business (Details Textual) $ in Millions	3 Months Ended
	Sep. 30, 2016ft²	Jan. 13, 2016USD ($)	Dec. 31, 2015
BRAZIL
Nature of Business [Line Items]
Equity Method Investment, Ownership Percentage	99.00%
Second Eastern Affilate [Member]
Nature of Business [Line Items]
Area of Land | ft²	139,000
iBio CMO LLC [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Lease Term	34 years
iBio CMO [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			100.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		70.00%
iBio CMO [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Amount Represented by Preferred Stock | $		$ 15
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		30.00%

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May 15, 2015	Apr. 13, 2016	Jan. 25, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Basis of Presentation [Line Items]
Accumulated deficit				$ (60,652)		$ (57,591)
Net Cash Used in Operating Activities				(2,273)	$ (1,147)
Stock Issued During Period, Shares, New Issues		6,500,000
Cash and Cash Equivalents, at Carrying Value, Total				$ 20,098	$ 8,384	$ 23,014	$ 9,494
Common Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Aspire Capital Fund Llc [Member] | Maximum [Member]
Basis of Presentation [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 15,000
iBio CMO [Member] | Eastern [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			3,500,000
Stock Issued During Period, Shares, Acquisitions			10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share				$ 0.622
Class Of Warrants Or Rights Exercised			1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.53
Proceeds From Capitalization Received			$ 15,000
Stock Issued During Period, Value, Acquisitions			$ 7,200

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Summary Of Significant Accounting Policies [Line Items]
Revenue from Grants	$ 36	$ 0
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15 years
Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	10 years
Intellectual Property [Member] | Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	16 years
Intellectual Property [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	23 years

Fixed Assets (Details)

Fixed Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment, Gross	$ 26,508	$ 26,179
Accumulated depreciation - assets under capital lease	(882)	(571)
Accumulated depreciation - other	(46)	(34)
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(928)	(605)
Net fixed assets	25,580	25,574	$ 10
Facility under capital lease [Member]
Property, Plant and Equipment, Gross	20,000	20,000
Equipment under capital lease [Member]
Property, Plant and Equipment, Gross	6,000	6,000
Facility improvements [Member]
Property, Plant and Equipment, Gross	57	42
Medical equipment [Member]
Property, Plant and Equipment, Gross	305	0
Office equipment and software [Member]
Property, Plant and Equipment, Gross	$ 146	$ 137

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Depreciation, Total	$ 324,000	$ 1,000
iBio CMO LLC [Member] | Second Eastern Affilate [Member]
Lease Term	34 years
Capital Leased Assets [Member]
Depreciation, Total	$ 311,000	$ 0

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, gross carrying value	$ 5,384	$ 5,365
Finite-Lived Intangible Assets, accumulated amortization	(3,361)	(3,273)
Net intangible assets	2,023	2,092
Intellectual property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, gross carrying value	3,100	3,100
Finite-Lived Intangible Assets, accumulated amortization	(1,971)	(1,932)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, gross carrying value	2,284	2,265
Finite-Lived Intangible Assets, accumulated amortization	$ (1,390)	$ (1,341)

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 88	$ 91
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Maximum [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	23 years
Minimum [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years

Significant Vendors (Details Te

Significant Vendors (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2016
Significant Vendor [Line Items]
Accounts Payable, Current	$ 979,000			$ 1,177,000
Accrued Liabilities, Current	1,022,000			920,000
Research and Development Expense	820,000	$ 551,000
Revenue, Net, Total	135,000	160,000
Amended Agreement [Member]
Significant Vendor [Line Items]
Research and Development Expense			$ 2,100,000
Revenue, Net, Total	62,000	160,000
Fraunhofer [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	122,000			341,000
Accrued Liabilities, Current	62,000			122,000
Novici [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	239,000			$ 200,000
Research and Development Expense	$ 239,000	$ 227,000

Capital Lease Obligation (Detai

Capital Lease Obligation (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
2,017	$ 2,100,000
2,018	2,100,000
2,019	2,100,000
2,020	2,100,000
2,021	2,100,000
Thereafter	59,850,000
Total minimum lease payments	70,350,000
Less: current portion	(173,000)	$ (170,000)
Long-term portion of minimum lease obligations	25,220,000	$ 25,265,000
Principal [Member]
2,017	173,048
2,018	186,593
2,019	201,198
2,020	216,947
2,021	233,928
Thereafter	24,381,531
Total minimum lease payments	25,393,245
Less: current portion	(173,048)
Long-term portion of minimum lease obligations	25,220,197
Interest [Member]
2,017	1,926,952
2,018	1,913,407
2,019	1,898,802
2,020	1,883,053
2,021	1,866,072
Thereafter	35,468,469
Total minimum lease payments	$ 44,956,755

Capital Lease Obligation (Det39

Capital Lease Obligation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Capital Leases, Income Statement, Interest Expense	$ 484,000	$ 0
Sub Lease Expiration Period	34 years
Operating Leases, Rent Expense	$ 2,100,000
Capital Lease Obligation Description	The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Apr. 07, 2016	Jan. 13, 2016	May 15, 2015	Apr. 13, 2016	Jan. 25, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	May 29, 2015
Stockholders' Equity [Line Items]
Preferred Stock, Shares Authorized						1,000,000		1,000,000
Common Stock, Shares Authorized						175,000,000	175,000,000	175,000,000
Proceeds from Warrant Exercises						$ 0	$ 63,000
Stock Issued During Period, Shares, New Issues				6,500,000
Stock Issued During Period, Value, New Issues				$ 4,043,000
Registration Common Stock									$ 15,000,000
Common Stock, Par or Stated Value Per Share						$ 0.001		$ 0.001
Stockholders [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, Other	6,500,000
Eastern Share Purchase Agreements [Member]
Stockholders' Equity [Line Items]
Proceeds from Warrant Exercises					$ 945,000
Stock Issued During Period, Value, New Issues					$ 2,177,000
Stock Issued During Period, Shares, Other		6,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.53
Stock Issued During Period, Shares, Acquisitions		3,500,000
Common Stock, Par or Stated Value Per Share		$ 0.622
Class Of Warrants Or Rights Exercised					1,784,000
Maximum Common Stock Percentage		38.00%
Eastern Share Purchase Agreements [Member] | Stockholders [Member]
Stockholders' Equity [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.622
Aspire Capital Fund, LLC 2014 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						15,000,000
Aggregate Common Stock Purchased			$ 15,000,000
Percentage Of Aggregate Shares Of Company						35.00%
Percentage Of Closing Price Of Common Stock						80.00%
Percentage Of Volume Weighted Average Price						97.00%
Stock Issued During Period, Shares, Other						150,000
Share Price						$ 0.40
Aspire Capital Fund, LLC 2015 [Member]
Stockholders' Equity [Line Items]
Commitment Shares Issued During Period			450,000
Maximum Amount Available For Purchase Of Shares						$ 15,000,000
Aspire Capital Fund, LLC 2015 [Member] | Aspirre Purchase Agreement 2015 [Member]
Stockholders' Equity [Line Items]
Percentage Of Common Stock Outstanding						19.99%
Commitment Shares Issued During Period						450,000
Stock Issued During Period, Shares, Other						15,343,406
Aspire Capital Fund Llc [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 500,000
Stock Issued During Period, Shares, Other			200,000
Additional Purchase Of Shares			2,000,000

Earnings (Loss) Per Common Sh41

Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Basic and diluted numerator:
Net loss available to iBio, Inc. stockholders	$ (3,061)	$ (1,805)
Basic and diluted denominator:
Weighted-average common shares outstanding	89,109	77,307
Per Share Amount	$ (0.03)	$ (0.02)

Earnings (Loss) Per Common Sh42

Earnings (Loss) Per Common Share (Details Textual) - shares shares in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Warrant [Member]
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants		6
Employee Stock Option [Member]
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants	12.3	12.1

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 265	$ 329
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	6	5
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 259	$ 324

Share-Based Compensation (Det44

Share-Based Compensation (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Outstanding at beginning of the period	12,273,334
Stock Options, Granted	0
Stock Options, Outstanding at end of the period	12,273,334	12,273,334
Stock Options, Vested and, as of September 30, 2016, expected to vest	12,233,897
Stock Options, Exercisable as of September 30, 2016	9,361,697
Weighted-average Exercise Price, Outstanding at beginning of the period	$ 1.31
Weighted-average Exercise Price, Outstanding at end of the period	1.31	$ 1.31
Weighted-average Exercise Price, Vested and, as of September 30, 2016, expected to vest	1.31
Weighted-average Exercise Price, Exercisable as of September 30, 2016	$ 1.31
Weighted-average Remaining Contractual Term (in years), Outstanding	6 years 1 month 6 days	6 years 4 months 24 days
Weighted-average Remaining Contractual Term (in years), Vested and, as of September 30, 2016, expected to vest	6 years 1 month 6 days
Weighted-average Remaining Contractual Term (in years), Exercisable as of September 30, 2016	5 years 6 months
Aggregate Intrinsic Value ,Outstanding	$ 433	$ 993
Aggregate Intrinsic Value, Vested and, as of September 30, 2016, expected to vest	433
Aggregate Intrinsic Value, Exercisable as of September 30, 2016	$ 405

Share-Based Compensation (Det45

Share-Based Compensation (Details Textual) shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2016USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	2.7
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	15
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars) | $	$ 1.4
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 8 months 5 days

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended			3 Months Ended
	Apr. 13, 2016	Dec. 31, 2015	Nov. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current				$ 239,000		$ 200,000
Operating Leases, Rent Expense				$ 2,100,000
Stock Issued During Period, Shares, New Issues	6,500,000
Common Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Stock Issued During Period, Value, New Issues	$ 4,043,000
Proceeds from Warrant Exercises				$ 0	$ 63,000
Eastern Two Share Purchase Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues				10,000,000
Common Stock, Par or Stated Value Per Share				$ 0.622
Class Of Warrants Or Rights Exercised				1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.53
Stock Issued During Period, Value, New Issues				$ 6,220,000
Proceeds from Warrant Exercises				$ 945,000
Eastern Capital Limited and its Affiliates [Member] | Retained Interest [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				70.00%
Eastern Capital Limited and its Affiliates [Member] | iBio CMO LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Due from (to) Related Party, Total				$ 15,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				30.00%
Second Eastern Affilate [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current				$ 772,000		$ 623,000
Interest Expense, Debt				483,000	0
Other General And Administrative Expense				$ 167,000	0
Second Eastern Affilate [Member] | iBio CMO LLC [Member]
Related Party Transaction [Line Items]
Lease Term				34 years
Stockholders [Member] | Standstill Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues				6,500,000
Director [Member] | Standstill Agreements [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage				38.00%
Related Party [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense		$ 2,500	$ 2,200	$ 7,500	$ 6,600

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jan. 14, 2014	Dec. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 01, 2014	Apr. 30, 2014	Dec. 30, 2013	Nov. 30, 2013	Apr. 30, 2013
Commitments and Contingencies [Line Items]
Research and Development Expense, Total			$ 820,000	$ 551,000
Royalty Guarantees, Commitments, Amount			$ 200,000
Long Term Purchase Commitment Expire Date			Dec. 31, 2015
Commitments [Member]
Commitments and Contingencies [Line Items]
Research Services Agreements Value Fulfilling Commitment		$ 3,000,000
Research and Development Expense, Total			$ 2,700,000
License Costs	$ 30,627
Initial license fee	20,000
Contractual Obligation, Due in Next Twelve Months								$ 78,000
Contractual Obligation, Due in Second Year						$ 161,754
Settlement Agreement [Member]
Commitments and Contingencies [Line Items]
Prepaid Expense							$ 1,000,000		$ 1,000,000	$ 1,000,000
Amended Agreement [Member]
Commitments and Contingencies [Line Items]
Research and Development Expense, Total					$ 2,100,000
Minimum [Member] | Commitments [Member]
Commitments and Contingencies [Line Items]
License Costs	25,000
Maximum [Member] | Commitments [Member]
Commitments and Contingencies [Line Items]
License Costs	$ 150,000
Fraunhofer [Member]
Commitments and Contingencies [Line Items]
Royalty Guarantees, Commitments, Amount		$ 3,000,000	$ 4,000,000
Other Commitments, Description			under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties.

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands		3 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Segment Reporting Information [Line Items]
Revenues - external customers		$ 135	$ 160
Revenues - intersegment		0	0
Research and development		820	551
General and administrative		2,469	1,422
Operating loss		(3,154)	(1,813)
Interest expense		(483)	0
Interest and other income		25	8
Consolidated net loss		(3,612)	(1,805)
Total assets		48,091	11,374	$ 51,600
Fixed assets, net		25,580	10	25,574
Intangible assets, net		2,023	2,284	$ 2,092
Depreciation expense		324	1
Amortization of intangible assets		88	91
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers		49
Revenues - intersegment		182
Research and development		321
General and administrative		1,271
Operating loss		(1,361)
Interest expense		(483)
Interest and other income		7
Consolidated net loss		(1,837)
Total assets		36,330
Fixed assets, net		25,572
Intangible assets, net		0
Depreciation expense		323
Amortization of intangible assets		0
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues - external customers		0	0
Revenues - intersegment		(334)	0
Research and development		(185)	0
General and administrative		(149)	0
Operating loss		0	0
Interest expense		0	0
Interest and other income		0	0
Consolidated net loss		0	0
Total assets		(49)	0
Fixed assets, net		0	0
Intangible assets, net		0	0
Depreciation expense		0	0
Amortization of intangible assets		0	0
iBio, Inc. [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers		86	160
Revenues - intersegment		152	0
Research and development		684	551
General and administrative		1,347	1,422
Operating loss		(1,793)	(1,813)
Interest expense		0	0
Interest and other income		18	8
Consolidated net loss		(1,775)	(1,805)
Total assets		11,810	11,374
Fixed assets, net		8	10
Intangible assets, net		2,023	2,284
Depreciation expense		1	1
Amortization of intangible assets		$ 88	91
iBio CMO [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	[1]		0
Revenues - intersegment	[1]		0
Research and development	[1]		0
General and administrative	[1]		0
Operating loss	[1]		0
Interest expense	[1]		0
Interest and other income	[1]		0
Consolidated net loss	[1]		0
Total assets	[1]		0
Fixed assets, net	[1]		0
Intangible assets, net	[1]		0
Depreciation expense	[1]		0
Amortization of intangible assets	[1]		$ 0
[1]	iBio CMO commenced operations in December 2015.